CymaBay Therapeutics

CymaBay Therapeutics

World Rank (Jan-05-2024)
4,829
Market Cap (Jan-05-2024)
2.607 Billion USD
World Rank (Jul-30-2023)
7,868
Market Cap (Jul-30-2023)
1.197 Billion USD
World Rank (Jan-07-2022)
17,152
Market Cap (Jan-07-2022)
0.280 Billion USD
World Rank (Jan-01-2021)
12,226
Market Cap (Jan-01-2021)
0.403 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
CBAY
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-93 Million USD
Annual Net Income in USD
-106 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
141 Million USD
Total Liabilities in USD
105 Million USD
Total Equity in USD
36 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
HealthCare Products
Biotechnology
Biopharmaceutical
Company Website
CYMABAY THERAPEUTICS
Yahoo
Yahoo @ Frankfurt
Company Profile
CymaBay Therapeutics is a Clinical Stage Biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. The company estimated annual revenue is currently 6.8 million USD per year. The headquarters is in USA.
Founded Year
1988
Stock Exchange
Nasdaq
Frankfurt
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share